secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001034842-26-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q1 revenue up 26% to $58.8M, net income $8.7M; reaffirms FY2026 guidance
------------------------------------------------------------------------------

- Q1 total revenues $58.8M (net product sales $54.9M, contract $3.9M), up 26% YoY.
- Net income $8.7M ($0.44 diluted EPS) vs. $11.4M ($0.63 diluted) in Q1 2025.
- TAVALISSE sales $37.3M (+31%), GAVRETO $9.6M (+7%), REZLIDHIA $8.0M (+31%).
- Eli Lilly to terminate ocadusertib collaboration effective June 15, 2026.
- Restructured $40M MidCap revolver; repaid $40M term loan, drew $8M on new facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/0001034842-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/rigl-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer